FGF21 Variants Resolving Stability and Potency Trade-offs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Human wild type FGF21 and known variants face challenges with low potency and pharmaceutical stability, including proteolytic degradation, oxidation, aggregation, and post-translational modifications, which affect their efficacy in treating type 2 diabetes, obesity, dyslipidemia, and metabolic syndrome.
Innovation Solution
Development of alternative FGF21 variants with specific amino acid substitutions such as A31C, G43C, D127K, S167R, G174L, L98D, L100K, Y179F, and G170E, which enhance potency and stability by reducing proteolytic degradation, aggregation, and improving thermal and preservative compatibility, while maintaining biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human wild type FGF21 or known variants are used, then the molecule can be produced, but the potency is low and pharmaceutical stability is poor
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions at defined positions (e.g., A31C, G43C, D127K, S167R, G174L, L98D, L100K, Y179F, G170E) to modify the protein's biochemical properties. These substitutions alter the molecule's stability, potency, and resistance to degradation, transforming it from an unstable low-potency variant into a stable high-potency therapeutic candidate.
Solution Approach 2:
The patent creates a composite protein structure by combining multiple amino acid substitutions that work synergistically. The variant incorporates stabilizing substitutions (A31C, G43C) alongside potency-enhancing substitutions (D127K, S167R, G174L), resulting in a composite molecule that achieves both improved stability and enhanced potency simultaneously.
2Reliability
If FGF21 is administered to treat metabolic conditions, then therapeutic effect is achieved, but proteolytic degradation occurs
Solution Approach 1:
The patent applies preliminary anti-action by introducing amino acid substitutions that preemptively block proteolytic cleavage sites. The substitutions at positions 31, 43, and other critical residues create structural modifications that prevent proteases from recognizing and degrading the FGF21 molecule, thereby protecting it from proteolytic degradation before it can occur in the body.
Solution Approach 2:
The patent modifies the protein's resistance to proteolysis by changing specific amino acid parameters. Substitutions such as A31C and G43C alter the local structural and chemical properties of the protein, making it resistant to proteolytic enzymes while maintaining its biological activity and therapeutic effectiveness.
3Power
If FGF21 is used at high concentrations for therapeutic effect, then treatment efficacy increases, but aggregation occurs
Solution Approach 1:
The patent applies parameter changes by introducing amino acid substitutions that modify the protein's surface properties and intermolecular interaction characteristics. Substitutions such as L98D, L100K, and Y179F alter the protein's charge distribution, hydrophobicity, and conformational stability, preventing aggregation even at high concentrations while maintaining full therapeutic efficacy.
Solution Approach 2:
The patent creates a composite protein structure that inherently resists aggregation through multiple stabilizing substitutions. The combination of substitutions (A31C, G43C, L98D, L100K, Y179F) works synergistically to maintain protein solubility and prevent self-association, allowing high concentrations to be administered without aggregation.
4Reliability
If FGF21 is produced in mammalian cell systems, then biological activity is achieved, but post-translational modifications and proteolysis occur during production
Solution Approach 1:
The patent applies parameter changes by introducing amino acid substitutions that prevent unwanted post-translational modifications during mammalian cell production. Substitutions at critical positions (A31C, G43C, Y179F) block enzymatic modification sites, ensuring the protein is produced in its desired form without unwanted glycosylation, phosphorylation, or other modifications that would reduce its activity or stability.
Data Source
AI summary
This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants.